Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2020), Nature

Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.

Bowyer G. et al, (2020), The Journal of experimental medicine, 217

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham SP. et al, (2020)

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

van Doremalen N. et al, (2020), Science Advances, 6, eaba8399 - eaba8399

The early landscape of COVID‐19 vaccine development in the UK and rest of the world

Sharpe HR. et al, (2020), Immunology

A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector

Sebastian S. et al, (2020), Vaccines, 8, 241 - 241

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2020), bioRxiv : the preprint server for biology

CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells

Brenna E. et al, (2020), Cell Reports, 30, 137 - 152.e5

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Graham SP. et al, (2020), NPJ vaccines, 5

MVA-NP+M1 vaccine activates mucosal M1-specific T cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue.

Puksuriwong S. et al, (2019), The Journal of infectious diseases

Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.

Alharbi NK. et al, (2019), Scientific reports, 9

Vaccine platforms for the prevention of Lassa fever.

Purushotham J. et al, (2019), Immunology letters, 215, 1 - 11

An effective multi-pathogen vaccine targeting filoviruses and an arenavirus

Flaxman A. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1690 - 1691

Repertoire sharing between CD4(+) T follicular helper cells in peripheral blood and tonsil

Brenna E. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 424 - 425

Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice

Asthagiri Arunkumar G. et al, (2019), Vaccine, 37, 5567 - 5577

A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters.

van Doremalen N. et al, (2019), PLoS neglected tropical diseases, 13

HLA‐E: exploiting pathogen‐host interactions for vaccine development

Sharpe HR. et al, (2019), Clinical & Experimental Immunology

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge.

McMahon M. et al, (2019), Frontiers in Immunology, 10

A naturally protective epitope of limited variability as an influenza vaccine target

Thompson CP. et al, (2018), Nature Communications, 9

Load More

1
2
3
4
5

Include forthcoming?